Key Performance
More- Earnings Score: N/A
- Momentum Score: 31
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
Theriva Biologics announced upcoming presentation of additional data from the VIRAGE Phase 2b clinical trial of VCN-01 at the AACR 2026 Annual Meeting. The tumor response, biomarker, and subgroup analyses support an immune-mediated mechanism of action and demonstrate improved patient outcomes, including in patients with hepatic metastases. The company has reached agreement with FDA and EMA on a Phase 3 pivotal trial design for VCN-01 combined with gemcitabina/nab-paclitaxel for first-line treatment of metastatic pancreatic cancer.
04/18/2026, 1:17 PM • GlobeNewswire
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum
Small- and mid-cap stocks are gaining momentum on execution milestones and transformative deals. Interactive Strength surged 40% after acquiring Ergatta to boost revenue guidance by 50%. Kraig Biocraft Laboratories activated its 2026 production program for spider silk manufacturing. Theriva Biologics out-licensed an asset to focus on its pancreatic cancer program, while PMGC Holdings' subsidiary filed patents for animal health applications.
02/19/2026, 11:00 AM • GlobeNewswire
Theriva Biologics announced that clinical and safety results from a Phase 1 study of VCN-01 (zabilugene almadenorepvec) for refractory retinoblastoma will be presented at the 41st Asia-Pacific Academy of Ophthalmology Congress in Hong Kong on February 7, 2026. The presentation will include preclinical data demonstrating synergistic antitumor activity when combining topotecan with VCN-01, potentially improving outcomes for patients with difficult-to-treat vitreous seeding.
02/03/2026, 8:00 AM • GlobeNewswire
Theriva Biologics received favorable scientific advice from the European Medicines Agency (EMA) on the design of a Phase 3 clinical trial for VCN-01 in combination with gemcitabine/nab-paclitaxel for treating metastatic pancreatic ductal adenocarcinoma (PDAC). The EMA approved the proposed trial design, sample size, and adaptive design elements. The company plans to meet with the FDA in H1 2026 for a multinational Phase 3 trial and has cash runway through Q1 2027.
12/29/2025, 8:00 AM • GlobeNewswire
Theriva Biologics Provides Response to Unusual Market Action
Theriva Biologics reported unusual trading activity in its stock on October 24, 2025, and stated there are no material undisclosed developments causing the market action. The company is developing cancer therapeutics and has recently presented expanded data from its VIRAGE trial at ESMO 2025.
10/24/2025, 2:31 PM • GlobeNewswire
Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results
Theriva Biologics announced positive Phase 2b VIRAGE trial results for VCN-01 in metastatic pancreatic cancer, with improved overall survival and progression-free survival. The company is preparing for a potential Phase 3 trial and presented retinoblastoma study data at ASCO 2025.
08/11/2025, 8:00 AM • GlobeNewswire
Peers
- BCTXZBCTX WT
$0.08-0.61%Market CapN/A1-Year Change-92.16%
Statistics
MoreInformation as of 06/02/2026
Company Profile
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. Its lead product candidate, VCN-01 (zabilugene almadenorepvec), a clinical stage oncolytic human adenovirus that is in Phase 1 clinical trials and Phase 2 VIRAGE trial for patients with pancreatic cancer, head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer, and retinoblastoma. The company also develops VCN-11 for treating solid tumors; SYN-004 (ribaxamase), an oral capsule prophylactic therapy that is in Phase 1b/2a clinical trials for the prevention of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant (HCT); and SYN-020, a recombinant oral formulation of the enzyme intestinal alkaline phosphatase (IAP) for multiple gastrointestinal and metabolic indications. In addition, it develops clinical stage products, such as SYN-006 to prevent aGVH, clostridioides difficile infection, and microbiome damage in patients treated with carbapenem antibiotics; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. The company has a license agreement with Rasayana Therapeutics, Inc. to research, develop, manufacture, and commercialize any product that includes SYN-020, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.